Curis Names Daniel Passeri Senior Vice President of Corporate Development and Strategic Planning.Business/Science Editors CAMBRIDGE, Mass.--(BW HealthWire)--Nov. 29, 2000 Curis, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRIS) today announced the appointment of Daniel R. Passeri as senior vice president, corporate development and strategic planing Mr. Passeri comes to Curis from Gene Logic Inc, where he was senior vice president, corporate development. At Gene Logic, he was responsible for negotiating and overseeing alliance programs, managing the company's intellectual property portfolio and overall corporate development. Mr. Passeri was previously director of technology management at Boehringer Mannheim, where he established and coordinated business development projects through technology acquisitions and corporate ventures. His prior positions at the National Institutes of Health, New England Biolabs New England Biolabs (NEB) produces and supplies reagents for the life science industry. NEB offers a large selection of recombinant and native enzymes for genomic research. It also offers products in the areas related to proteomics and drug discovery. , Inc. and the U.S. Patent and Trademark Office involved technology transfer, patent prosecution Patent prosecution describes the interaction between an applicant, or their representative, and a patent office with regard to a patent, or an application for a patent. Broadly, patent prosecution can be split into pre-grant prosecution, which involves negotiation with a patent , and the evaluation of commercial and marketing strategies. "Dan Passeri's extensive background in corporate development, licensing and program management will serve Curis well as we shape and add depth to our broad portfolio of technologies and product opportunities in regenerative medicine," said Doros Platika, M.D., president and chief executive officer of Curis. "In addition, his experience in negotiating corporate alliances will help make possible the timely development of certain programs that target large markets and consequently will require the resources and commercialization infrastructure of larger partners. Dan is a superb strategic thinker and implementer. He will spearhead an aggressive corporate strategy to ensure that Curis is the premier regenerative medicine company. " Mr. Passeri earned a J.D. from the National Law Center at George Washington University George Washington University, at Washington, D.C.; coeducational; chartered 1821 as Columbian College (one of the first nonsectarian colleges), opened 1822, became a university in 1873, renamed 1904. , with an emphasis on intellectual property, licensing, contract law, negotiations and international business transactions. He holds an M.Sc. in biotechnology from the University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies and is a cum laude cum lau·de adv. & adj. With honor. Used to express academic distinction: graduated cum laude; 25 cum laude graduates. graduate of Northeastern University Northeastern University, at Boston, Mass.; coeducational; founded 1898 as a program within the Boston YMCA, inc. 1916, university status 1922, fully independent of the YMCA 1948. . Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology Developmental biology A large field of investigation that includes the study of all changes associated with an organism as it progresses through the life cycle. The life cycles of all multicellular organisms exhibit many similarities. with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com. The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. The completion of a successful pre-clinical trial does not mean the Company will be able to successfully commercialize the product. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000 and Quarterly Report on Form 10-Q Form 10-Q See 10-Q. filed with the Securities and Exchange Commission on August 14, 2000. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion